Navigation Links
Sorrento Therapeutics Completes Acquisition of Concortis Biosystems
Date:12/19/2013

uel our R&D pipeline over the long-term," said Henry Ji, Ph.D., President and CEO of Sorrento. "The successes of first-generation ADCs have paved a path for new conjugation technologies. Our ownership of each of the key components of an ADC – the antibody, conjugation chemistry, linkers, and toxins – gives us a distinct and unique advantage in the field."

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics is an oncology company developing a deep pipeline of new product candidates for the treatment of cancer and associated pain. Sorrento is advancing Cynviloq, a next-generation paclitaxel, into a Phase 3 clinical trial via the abbreviated 505(b)(2) pathway. Sorrento is also developing Resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the National Institutes of Health to treat terminal cancer patients suffering from intractable pain. The company has also developed a diverse library of fully functional monoclonal antibodies, complemented by a comprehensive ADC platform comprised of wholly owned conjugation chemistry, linkers and toxic payloads. Sorrento's multi-pronged approach to combating cancer with small molecules, antibodies, and ADCs provides optionality in addressing the complexity of cancer.

Forward-Looking Statements

This press release contains forward-looking statements under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected.  Forward-looking statements include statements about the potential for products to be successfully developed using the Concortis technologies; the synergies and prospects for a combined enterprise going forward, including the retention of key personnel; and the clinical development and commercial potential of conjugated antibodies that may be developed based on
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
2. Sorrento Therapeutics Adopts Stockholder Rights Plan
3. Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity
4. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
5. Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
6. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
7. Sorrento Therapeutics Completes IgDraSol Merger
8. Sorrento Therapeutics to Present at Two Healthcare Conferences
9. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
10. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
11. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Cogentix Medical, Inc. (NASDAQ: CGNT ), a ... release financial results for the first quarter of fiscal year ... on Monday, August 10, 2015. The Company ... results on Monday, August 10, 2015 at 4:30 p.m. Eastern ... and Chief Executive Officer, and Brett Reynolds , Chief ...
(Date:7/29/2015)... 29, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... announced that it will release Second Quarter financial ... 2015. AcelRx management will host an investment-community conference ... Pacific Time) on Aug 3rd, 2015 to discuss ...
(Date:7/29/2015)... , July 29, 2015  Efforts to improve working ... of pharmaceutical firms in North America ... is that an effective working capital management will ease ... patent cliffs. Big pharma companies expect to invest in ... Logo - http://photos.prnewswire.com/prnh/20150724/241957LOGO Analysis ...
Breaking Medicine Technology:Cogentix Medical to Announce First Quarter Fiscal 2016 Results on August 10, 2015 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 3AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 4Working Capital Management Seizes Priority in North American and European Pharma Industry 2Working Capital Management Seizes Priority in North American and European Pharma Industry 3Working Capital Management Seizes Priority in North American and European Pharma Industry 4
... Clinicians Concerned About ... Exposure When Using an Oral NSAID, TAMPA, Fla., ... leading global specialty pharmaceutical company, announced today that two,studies ... Society annual,meeting demonstrate the efficacy, tolerability and positive pharmacokinetic,profile ...
... Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced ... 1 clinical trial of a drug candidate under ... treat psychiatric disorders.,The drug candidate is a novel ... psychiatric disorder., "We are very happy to ...
Cached Medicine Technology:Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 3
(Date:7/29/2015)... ... ... " mybody ” was featured on NewsWatch as part of its monthly ... impact in their industry. Andrew Tropeano, the host of NewsWatch and business expert, conducted ... designed to strengthen the skin’s defense system from the inside out. , According to ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... entered into a partnership with 247Ergo, an ergonomics specialty firm. Purpose of the ... projects that the companies undertake could improve worker mobility, functionality and fitness levels. ...
(Date:7/29/2015)... Washington, DC (PRWEB) , ... July 29, 2015 ... ... and aluminum-related illnesses is seeking funding for a study on the potentially lifesaving ... Safety Research Institute today . , The research proposal is based on ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Hernia repairs ... advanced as a result. Information provided by the National Center for Health Statistics ... and three million new cases are reported annually. While the only effective treatment for ...
(Date:7/29/2015)... ... July 29, 2015 , ... Nature’s Artisan, a new ... of gourmet flavors. , Nature’s Artisan was founded by Tina Yarandi, who came up ... the UCLA School of Dentistry. Tina was amazed when she learned about the incredible ...
Breaking Medicine News(10 mins):Health News:Strengthen the Skin’s Defense System from the Inside Out with mybody 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 3Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 2Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 3Health News:National Statistics Reflect NCMA General Surgery Physicians Findings: Hernia Patients Who Seek Treatment Promptly are More Likely to Enjoy a Quick Recovery 2Health News:National Statistics Reflect NCMA General Surgery Physicians Findings: Hernia Patients Who Seek Treatment Promptly are More Likely to Enjoy a Quick Recovery 3Health News:Discover a New Take on Oral Care with Nature’s Artisan Gourmet Mouthwashes 2
... Language is sometimes a barrier for patients when ... prescription label language barrier increases the risk that a ... the benefit or suffer an adverse drug event. , ... that translate medication instructions and drug auxiliary warnings, and ...
... , NEW YORK, June 8 Cooper Martin, LLC ... line of medical and recovery care clothing that is both ... Martin clothing is ideal for those undergoing rehabilitation, recovering from ... or limited mobility. , , "Currently those with ...
... help the body to fight off the flu bug may ... doesn,t mean vaccines are bad, it just may help explain ... Dr. Andrew Mellor, director of the Immunotherapy Center at the ... in Molecular Immunogenetics. His team along with viral immunology ...
... More than 45 million Americans suffer from headaches annually , ... National Headache Foundation (NHF), EHE International is helping raise awareness about ... a unique approach, the NHF and EHE are featuring "You ... ... window at 10 Rockefeller Plaza, for the month of June, to ...
... WASHINGTON, June 8 The below listed groups issued ... Advisory Committee Meeting on June 9-10: , , ... strongly urge the FDA to carefully consider the importance ... in pediatric and adolescent populations. Access to safe ...
... , Wireless Standard added to Continua Health Alliance Design ... /PRNewswire/ -- The ZigBee(R) Alliance announced today ... Care as Continua,s new low power local area network ... supporting thousands of devices on a single network. Continua ...
Cached Medicine News:Health News:Robot Speaks Many Languages - Improves Pharmacy Patient Outcomes 2Health News:Cooper Martin Unveils Innovative, Stylish Recovery Clothing for Those with Limited Mobility 2Health News:Researchers work to boost effectiveness of the flu vaccine 2Health News:Researchers work to boost effectiveness of the flu vaccine 3Health News:EHE International Supports the National Headache Foundation 2Health News:Joint Statement on Atypical Antipsychotic Use in Children 2Health News:Joint Statement on Atypical Antipsychotic Use in Children 3Health News:ZigBee Selected by Continua Health Alliance for Next Generation Guidelines 2Health News:ZigBee Selected by Continua Health Alliance for Next Generation Guidelines 3
S.O.C. Medium...
... The Evolve™ modular radial head system ... and clinical research to create the next ... creating a two part, modular design, the ... to appropriately match the patients anatomy. In ...
This legless table has adjustable height and round post. Pad sold separately....
This table has a rectangular top, adjustable height, integral leg, and rail clamp.,Standard 2" (5 cm) pad included....
Medicine Products: